The Prognostic Value of PD-L1 Expression in Triple-Negative Breast Cancer: A Cohort Study and Systematic Literature Review

Crossmark: check for updates

Authors

  • Daniel Schmolze Pathology, City of Hope National Medical Center, Duarte, CA, USA
  • Carolyn E. Behrendt Biostatistics, Beckman Research Institute of the City of Hope, Duarte, CA, USA
  • Peter P. Lee Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA, USA
  • Sophia Apple Pathology, City of Hope National Medical Center, Duarte, CA, USA; Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

DOI:

https://doi.org/10.17140/PLMOJ-2-107

Keywords:

Breast, PD-L1, PD-1, Triple negative, Immune, Immuno-oncology, TNBC, TMA, Prognosis

Abstract

Context
The prognostic value of programmed death ligand-1 (PD-L1) in triple-negative breast cancer (TNBC) is unclear.
Objective
To investigate PD-L1 expression for association with survival.
Design
Surgical specimens of primary TNBC were linked to data on recurrence-free survival (RFS). Tissue microarray averaging 3 tumor
cores per case underwent immunohistochemical staining. Within each core, PD-L1 positivity was scored separately for tumor,
stromal, and immune cells by averaging readings by two board-certified pathologists. Having at least one core with high (above
10%) PD-L1 staining (on tumor cells as primary risk, on stromal and immune cells as secondary risks) was evaluated for association
with RFS using proportional hazards regression. Comparable survival analyses were identified by systematic search of MEDLINEindexed
journals through March 2019.
Results
Patients (n=112) contributed 308 cores of TNBC. During follow-up, TNBC recurred in 24 subjects; another 4 subjects died
without recurrence. Ten (8.9%) subjects had High PD-L1 expression on tumor cells, a feature associated with better RFS [hazards
ratio 0.44 (95% Confidence Interval 0.19-0.97)] independently of age, distant metastasis, tumor size, lymphovascular invasion, and
Ki-67. In contrast, High PD-L1 in stromal cells or immune cells was not associated with RFS. Among 22 similar studies, high PDL1
on tumor cells was associated with survival in 16 studies: 7 favorably, 8 unfavorably, and 1 with mixed results.
Conclusions
In this TNBC cohort, High PD-L1 on tumor cells conferred favorable prognosis. The lack of consensus across similar studies
suggests that future studies should explore how timing, microenvironment, and glycosylation influence PD-L1’s association with
survival.

References

Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7- H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012; 24(2): 207-212. doi: 10.1016/j.coi.2011.12.009

Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S. Immune checkpoint blockade to improve tumor infil-trating lymphocytes for adoptive cell therapy. Chan D, ed. PLoS One. 2016; 11(4): e0153053. doi: 10.1371/journal.pone.0153053

Wu C, Zhu Y, Jiang J, Zhao J, Zhang X-G, Xu N. Immunohisto-chemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006; 108(1): 19-24. doi: 10.1016/j.acthis.2006.01.003

Wang A, Wang HY, Liu Y, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analy-sis. Eur J Surg Oncol EJSO. 2015; 41(4): 450-456. doi: 10.1016/j. ejso.2015.01.020

Massi D, Brusa D, Merelli B, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol. 2014; 25(12): 2433-2442. doi: 10.1093/annonc/mdu452

Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016; 11(2): 143-148. doi: 10.1007/s11523- 015-0392-7

Guan J, Lim KS, Mekhail T, Chang C-C. Programmed Death Ligand-1 (PD-L1) expression in the programmed death recep-tor-1 (PD-1)/PD-L1 blockade: A key player against various can-cers. Arch Pathol Lab Med. 2017; 141(6): 851-861. doi: 10.5858/ arpa.2016-0361-RA

Ali HR, Glont S-E, Blows FM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associ-ated with infiltrating lymphocytes. Ann Oncol. 2015; 26(7): 1488- 1493. doi: 10.1093/annonc/mdv192

Guo Y, Yu P, Liu Z, et al. Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: A meta-analysis. PLoS One. 2016; 11(5): e0156323. doi: 10.1371/journal. pone.0156323

Baptista MZ, Sarian LO, Derchain SFM, Pinto GA, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2016; 47(1): 78-84. doi: 10.1016/j.humpath.2015.09.006

Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predic-tive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6(7): 5449-5464. doi: 10.18632/oncotarget.3216

Zhang M, Sun H, Zhao S, et al. Expression of PD-L1 and prognosis in breast cancer: A meta-analysis. Oncotarget. 2017; 8(19): 31347-31354. doi: 10.18632/oncotarget.15532

Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-neg-ative breast cancers: A critical review with an emphasis on the im-plications for pathologists and oncologists. Mod Pathol. 2011; 24(2): 157-167. doi: 10.1038/modpathol.2010.200

Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7): 2750- 2767. doi: 10.1172/JCI45014

Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013; 19(19): 5533-5540. doi: 10.1158/1078-0432.CCR-13-0799

García-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative breast cancer: The future of immune targeting. Clin Med Insights Oncol. 2016; 10s1: CMO. S34540. doi: 10.4137/CMO.S34540

Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrat-ing lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology (Phila). 2017;49(2):141-155. doi: 10.1016/j. pathol.2016.10.010

Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 ex-pression in triple-negative breast cancer. Cancer Immunol Res. 2014; Orginal Research | Volume 2 | Number 1 | Apple S 2(4): 361-370. doi: 10.1158/2326-6066.CIR-13-0127

Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One. 2014; 9(2): e88557. doi: 10.1371/journal.pone.0088557

Gibson J. Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol. 2015; 16(6): e264. doi: 10.1016/S1470- 2045(15)70208-1

Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 2016; 34(21): 2460-2467. doi: 10.1200/JCO.2015.64.8931

Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of dif-ferent cut-off levels of Ki-67 in breast cancer: A systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015; 153(3): 477-491. doi: 10.1007/s10549-015-3559-0

Sullivan SG, Greenland S. Bayesian regression in SAS software. Int J Epidemiol. 2013; 42(1): 308-317. doi: 10.1093/ije/dys213

Yeong J, Lim JCT, Lee B, et al. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple nega-tive breast cancer. J Immunother Cancer. 2019; 7(1): 34. doi: 10.1186/ s40425-019-0499-y

Lee J, Kim D-M, Lee A. Prognostic role and clinical associa-tion of tumor-infiltrating lymphocyte, programmed death ligand-1 expression with neutrophil-lymphocyte ratio in locally advanced triple-negative breast cancer. Cancer Res Treat. 2019; 51(2): 649-663. doi: 10.4143/crt.2018.270

Barrett MT, Lenkiewicz E, Malasi S, et al. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. Breast Cancer Res. 2018; 20(1): 71. doi: 10.1186/s13058-018-1004-0

Solinas C, Garaud S, De Silva P, et al. Immune checkpoint mol-ecules on tumor-infiltrating lymphocytes and their association with tertiary lymphoid structures in human breast cancer. Front Immunol. 2017; 8. doi: 10.3389/fimmu.2017.01412

Wang Z-Q, Milne K, Derocher H, Webb JR, Nelson BH, Wat-son PH. PD-L1 and intratumoral immune response in breast can-cer. Oncotarget. 2017; 8(31). doi: 10.18632/oncotarget.18305

AiErken N, Shi H, Zhou Y, et al. High PD-L1 expression is closely associated with tumor-infiltrating lymphocytes and leads to good clinical outcomes in Chinese triple negative breast cancer pa-tients. Int J Biol Sci. 2017; 13(9): 1172-1179. doi: 10.7150/ijbs.20868

Botti G, Collina F, Scognamiglio G, et al. Programmed death li-gand 1 (PD-L1) tumor expression is associated with a better prog-, et al 7 nosis and diabetic disease in triple negative breast cancer patients. Int J Mol Sci. 2017; 18(2): 459. doi: 10.3390/ijms18020459

Zhu X, Zhang Q, Wang D, Liu C, Han B, Yang J-M. Expression of PD-L1 attenuates the positive impacts of high-level tumor-infil-trating lymphocytes on prognosis of triple-negative breast cancer. Cancer Biol Ther. 2019; 1-8. doi: 10.1080/15384047.2019.1595282

Asano Y, Kashiwagi S, Goto W, et al. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. J Transl Med. 2018; 16(1): 87. doi: 10.1186/s12967-018-1458-y

Choi SH, Chang JS, Koo JS, et al. Differential prognostic im-pact of strong PD-L1 expression and 18F-FDG uptake in triple-negative breast cancer. Am J Clin Oncol. 2018; 41(11): 1049-1057. doi: 10.1097/COC.0000000000000426

Tomioka N, Azuma M, Ikarashi M, et al. The therapeutic can-didate for immune checkpoint inhibitors elucidated by the sta-tus of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer. 2018; 25(1): 34-42. doi: 10.1007/s12282- 017-0781-0

Adams TA, Vail PJ, Ruiz A, et al. Composite analysis of im-munological and metabolic markers defines novel subtypes of triple negative breast cancer. Mod Pathol. 2018; 31(2): 288-298. doi: 10.1038/modpathol.2017.126

Li Z, Dong P, Ren M, et al. PD-L1 expression is associated with tumor FOXP3 + regulatory T-Cell infiltration of breast can-cer and poor prognosis of patient. J Cancer. 2016; 7(7): 784-793. doi: 10.7150/jca.14549

Barrett MT, Anderson KS, Lenkiewicz E, et al. Genomic ampli-fication of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015; 6(28): 26483-26493. doi: 10.18632/oncotarget.4494

Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in hu-man breast cancer. Breast Cancer Res Treat. 2014; 146(1): 15-24. doi: 10.1007/s10549-014-2988-5

Byun KD, Hwang HJ, Park KJ, et al. T-Cell immunoglobulin mucin 3 expression on tumor infiltrating lymphocytes as a posi-tive prognosticator in triple-negative breast cancer. J Breast Cancer. 2018; 21(4): 406. doi: 10.4048/jbc.2018.21.e61 Submit your article to this journal | https://openventio.org/submit-manuscript/

Li M, Li A, Zhou S, et al. Heterogeneity of PD-L1 expres-sion in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer. 2018; 18(1): 4. doi: 10.1186/ s12885-017-3916-y

Brockhoff G, Seitz S, Weber F, et al. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. Oncotar-get. 2018; 9(5): 6201-6212. doi: 10.18632/oncotarget.23717

Guo L, Li W, Zhu X, et al. PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognos-tic biomarker. Springerplus. 2016; 5(1): 805. doi: 10.1186/s40064- 016-2513-x

Li X, Wetherilt CS, Krishnamurti U, et al. Stromal PD-L1 ex-pression is associated with better disease-free survival in triple-negative breast cancer. Am J Clin Pathol. 2016; 146(4): 496-502. doi: 10.1093/ajcp/aqw134

Sun WY, Lee YK, Koo JS. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med. 2016; 14(1): 173. doi: 10.1186/s12967- 016-0925-6

Mori H, Kubo M, Yamaguchi R, et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is as-sociated with a poor prognosis in triple-negative breast cancer. On-cotarget. 2017; 8(9): 15584-15592. doi: 10.18632/oncotarget.14698

Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade in-duces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528): 568-571. doi: 10.1038/nature13954

Gruosso T, Gigoux M, Manem VSK, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019; 129(4): 1785-1800. doi: 10.1172/ JCI96313

Keren L, Bosse M, Marquez D, et al. A structured tumor-im-mune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018; 174(6): 1373-1387. e19. doi: 10.1016/j.cell.2018.08.039

Shao B, Li C-W, Lim S-O, et al. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppres-sion in triple-negative breast cancer. Am J Cancer Res. 2018; 8(9): 1837-1846.

Downloads

Published

2019-05-18

How to Cite

Daniel Schmolze, Carolyn E. Behrendt, Peter P. Lee, & Sophia Apple. (2019). The Prognostic Value of PD-L1 Expression in Triple-Negative Breast Cancer: A Cohort Study and Systematic Literature Review. Pathology and Laboratory Medicine, 2(1), 1–8. https://doi.org/10.17140/PLMOJ-2-107

Issue

Vol. 2 No. 1 (2019): Volume 2 Issue 1 2019

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Pathology and Laboratory Medicine (PLM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.